II. Indications

III. Contraindications

  1. Recent major bleeding

IV. Mechanism

  1. Fab Antibody fragment
  2. Inhibits Platelet aggregation via Glycoprotein IIb/IIIa receptors on Platelet plasma membranes
  3. Inhibits Fibrinogen binding to Platelets

V. Dosing

  1. Percutaneous Coronary Intervention (PCI)
    1. Load: 0.25 mg/kg IV bolus given 10 to 60 minutes before PCI
    2. Infuse: 0.125 mcg/kg/min up to 10 mcg/min IV for 12 hours
  2. Unstable Angina or non-ST-elevation Myocardial Infarction pending PCI within 24 hours
    1. Dosing as for PCI, with infusion up to 18 to 24 hours, completing at one hour post-PCI
  3. Coronary Aneursym in Kawasaki Disease
    1. Off label use for age >2 months old
    2. Dosing as used in PCI

VI. Safety

  1. Unknown safety in pregnancy
  2. Unknown safety in Lactation
    1. Abciximab is excreted in human milk

VII. Resources

Images: Related links to external sites (from Bing)

Related Studies